1 Kahn, BB & Flier, JS (2000) Obesity and insulin resistance. J Clin Invest 106, 473–481.
2 Berg, AH, Combs, TP, Du, X, Brownlee, M & Scherer, PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7, 947–953.
3 Scherer, PE, Williams, S, Fogliano, M, Baldini, G & Lodish, HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270, 26746–26749.
4 Hu, E, Liang, P & Spiegelman, BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271, 10697–10703.
5 Fruebis, J, Tsao, TS, Javorschi, S, Ebbets-Reed, D, Erickson, MR, Yen, FT, Bihain, BE & Lodish, HF (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98, 2005–2010.
6 Combs, TP, Berg, AH, Obici, S, Scherer, PE & Rosetti, L (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108, 1875–1881.
7 Yamamoto, Y, Hirose, H, Saito, I, Tomita, M, Taniyama, M, Matsubara, K, Okazaki, Y, Ishii, T, Nishikai, K & Saruta, T (2002) Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 103, 137–144.
8 Tschritter, O, Fritsche, A, Thamer, C, Haap, M, Shirkavand, F, Rahe, S, Staiger, H, Maerker, E, Haring, H & Stumvoll, M (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239–243.
9 Pellme, F, Smith, U, Funahashi, T, Matsuzawa, Y, Brekke, H, Wiklund, O, Taskinen, MR & Jansson, PA (2003) Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 52, 1182–1186.
10 Hotta, K, Funahashi, T, Arita, Y, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20, 1595–1599.
11 Weyer, C, Funahashi, T, Tanaka, S, Hotta, K, Matsuzawa, Y, Pratley, RE & Tataranni, PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes, close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930–1935.
12 Yu, JG, Javorschi, S, Hevener, AL, Kruszynska, YT, Norman, RA, Sinha, M & Olefsky, JM (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51, 2968–2974.
13 Shea, SA, Hilton, MF, Orlova, C, Ayers, RT & Mantzoros, CS (2005) Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 90, 2537–2544.
14 Peake, PW, Kriteros, AD, Denyer, GS, Campbell, LV & Charlesworth, JA (2003) The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects. Int J Obes Relat Metab Disord 27, 657–662.
15 Imbeault, P, Pomerleau, M, Harper, ME & Doucet, E (2004) Unchanged fasting and postprandial adiponectin levels following a 4-day caloric restriction in young healthy men. Clin Endocrinol 60, 429–433.
16 Esposito, K, Nappo, F, Giugliano, F, Di Palo, C, Ciotola, M, Barbieri, M, Paolisso, G & Giugliano, D (2003) Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 78, 1135–1140.
17 English, PJ, Coughlin, SR, Hayden, K, Malik, IA & Wilding, JP (2003) Plasma adiponectin increases postprandially in obese, but not in lean, subjects. Obes Res 11, 839–844.
18 Lewis, GF, O'Meara, NM, Soltys, PA, Blackman, JD, Iverius, PH, Druetzler, AF, Getz, GS & Polonsky, KS (1990) Postprandial lipoprotein metabolism in normal and obese subjects, comparison after the vitamin A fat-loading test. J Clin Endocrinol Metab 71, 1041–1050.
19 Chen, YD, Swami, S, Skowronski, R, Coulston, A & Reaven, GM (1993) Differences in postprandial lipemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 76, 172–177.
20 Schrezenmeir, J, Keppler, I, Fenselau, S, Weber, P, Biesalski, HK, Probst, R, Laue, C, Zuchhold, HD, Prellwitz, W & Beyer, J (1993) The phenomenon of a high triglyceride response to an oral lipid load in healthy subjects and its link to the metabolic syndrome. Ann N Y Acad Sci 683, 302–314.
21 Couillard, C, Bergeron, N, Prud'homme, D, Bergeron, J, Tremblay, A, Bouchard, C, Mauriege, P & Despres, JP (1998) Postprandial triglyceride response in visceral obesity in men. Diabetes 47, 953–960.
22 Matthews, DR, Hosker, JP, Rudenski, AS, Naylor, BA, Treacher, DF & Turner, RC (1985) Homeostasis model assessment, insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419.
23 Adult Treatment Panel III (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 16, 2486–2496.
24 Monzillo, LU & Hamdy, O (2003) Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 61, 397–412.
25 Heliovaara, MK, Strandberg, TE, Karonen, SL & Ebeling, P (2006) Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Horm Metab Res 38, 336–340.
26 Caixas, A, Gimenez-Palop, O, Gimenez-Perez, G, Potau, N, Berlanga, E, Gonzalez-Glemente, JM, Arroyo, J, Laferrere, B & Mauricio, D (2006) Postprandial adiponectin levels are unlikely to contribute to the pathogenesis of obesity in Prader-Willi syndrome. Horm Res 65, 39–45.
27 Baratta, R, Amato, S, Degano, C, Farina, MG, Patane, G, Vigneri, R & Frittitta, L (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass, evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89, 2665–2671.
28 Fumeron, F, Aubert, R, Siddiq, A, et al. (2004) Epidemiologic data on the Insulin Resistance Syndrome (DESIR) Study Group. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period, the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 53, 1150–1157.
29 Vasseur, F, Helbecque, N, Dina, C, et al. (2002) Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 11, 2607–2614.